Payment overview · 2025
General Payments
$386.04
11 reported records · 6 companies
Healthcare provider profile · identity verified
Mitchell Lampert, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BOYNTON BEACH, FL · NPI 1588682678
Verified facts
What the public records show
CMS Open Payments records show Mitchell Lampert, M.D. received $386.04 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $129.00 | 33.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $124.38 | 32.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.84 | 11.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $43.21 | 11.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.08 | 6.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $20.53 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $386.04 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $129.00 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $124.38 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $43.84 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.84 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $43.21 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.08 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 92 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 918 | 246 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 663 | 210 |
| Atorvastatin Calcium | Atorvastatin Calcium | 648 | 192 |
| Amlodipine Besylate | Amlodipine Besylate | 502 | 143 |
| Simvastatin | Simvastatin | 400 | 117 |
| Pantoprazole Sodium | Pantoprazole Sodium | 399 | 129 |
| Losartan Potassium | Losartan Potassium | 346 | 101 |
| Alprazolam | Alprazolam | 323 | 110 |
| Metoprolol Succinate | Metoprolol Succinate | 312 | 92 |
| Escitalopram Oxalate | Escitalopram Oxalate | 301 | 86 |
| Lisinopril | Lisinopril | 265 | 75 |
| Omeprazole | Omeprazole | 263 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 254 | 75 |
| Synthroid | Levothyroxine Sodium | 248 | 69 |
| Valsartan | Valsartan | 227 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 224 | 70 |
| Temazepam | Temazepam | 176 | 47 |
| Metformin Hcl | Metformin Hcl | 172 | 62 |
| Allopurinol | Allopurinol | 145 | 43 |
| Gabapentin | Gabapentin | 140 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 40 |
| Trazodone Hcl | Trazodone Hcl | 132 | 52 |
| Finasteride | Finasteride | 130 | 35 |
| Montelukast Sodium | Montelukast Sodium | 130 | 40 |
| Azithromycin | Azithromycin | 128 | 110 |
| Fluoxetine Hcl | Fluoxetine Hcl | 123 | 34 |
| Carvedilol | Carvedilol | 121 | 32 |
| Sertraline Hcl | Sertraline Hcl | 116 | 32 |
| Meloxicam | Meloxicam | 115 | 43 |
| Fenofibrate | Fenofibrate | 114 | 32 |
| Tramadol Hcl | Tramadol Hcl | 112 | 40 |
| Methylprednisolone | Methylprednisolone | 111 | 88 |
| Famotidine | Famotidine | 109 | 42 |
| Lorazepam | Lorazepam | 108 | 25 |
| Furosemide | Furosemide | 101 | 33 |
| Bupropion Xl | Bupropion Hcl | 99 | 24 |
| Atenolol | Atenolol | 98 | 28 |
| Clonazepam | Clonazepam | 96 | 27 |
| Eliquis | Apixaban | 92 | 26 |
| Ezetimibe | Ezetimibe | 89 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 36 |
| Glimepiride | Glimepiride | 84 | 20 |
| Potassium Chloride | Potassium Chloride | 81 | 26 |
| Ozempic | Semaglutide | 78 | 21 |
| Celecoxib | Celecoxib | 77 | 30 |
| Ipratropium Bromide | Ipratropium Bromide | 71 | 26 |
| Irbesartan | Irbesartan | 70 | 18 |
| Diazepam | Diazepam | 69 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 68 | 23 |
| Xarelto | Rivaroxaban | 63 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 54 | 19 |
| Glipizide | Glipizide | 53 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 14 |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 41 |
| Donepezil Hcl | Donepezil Hcl | 45 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | 13 |
| Valacyclovir | Valacyclovir Hcl | 43 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 18 |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | 11 |
| Ramipril | Ramipril | 37 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 13 |
| Spironolactone | Spironolactone | 31 | 11 |
| Terazosin Hcl | Terazosin Hcl | 30 | suppressed |
| Cefdinir | Cefdinir | 29 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 19 |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $386.04 · 11 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ELIQUIS, GEMTESA, Leqembi, NURTEC ODT, TRELEGY ELLIPTA, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error